Targeting Microbiota 2018
Towards Clinical Revolution
Final Agenda

October 28 - 30, 2018 - Porto, Portugal
www.microbiota-site.com
6th World Congress on
Targeting Microbiota
Towards Clinical Revolution
October 28-30, 2018 - Porto, Portugal

Congress Sessions:
- Microbiota 2018: recent advances & challenges
- Recent analysis, methods, bioinformatics & interpretations
- Strategic role of metabolites and mediators on the microbiota-host cross-talk
- Strategies to manipulate microbiota & medicine of tomorrow

Key dates
Fri. Registration Oct. 12, 2018
Wed. Poster Submission Oct. 17, 2018

Microbiota 2018 Speakers

Recent advances on gut microbiota and food intolerances
Yurdagul Zopf
University of Erlangen-Nuremberg, Germany

Psycho neuroimmunology and gut microbes
Paul Forsythe
McMaster University, Canada

Targeted gut microbiota and short chain fatty acid profile among term and preterm infants
Jan Mazela
Poznan University of Medical Sciences, Poland

Honor thy lodgers? Interactions between the built environment microbiome and the human microbiome
Markus Egert
Furtwangen University, Germany

Phage therapy strategy to modulate the child stunting microbiota
Mohammadali Khan Mirzaei
McGill University, Canada

Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes
Julien Diana
Inserm, France

Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases
Maria Cecilia Olron
University of Padova, Italy

Sepsis and Microbiota: Obstacles, Recent Advances and strategies
Natalia Beloborodova
Negovsky Research Institute, Russia

Exploring the role of gut dysbiosis in neuroinflammation and hypertension
David Dungan
Baylor College of Medicine, USA

Impact of antibiotic treatment on the human microbiota - a review of the clinical implications
Maria Wehreschild
University Hospital of Cologne, Germany

Role of microbes in stem cells transplantation related complication
Ernst Holler
University Hospital Regensburg, Germany

MAUT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response
Antonio Riva
Institute of Hepatology London, United Kingdom

The effect of gut bacterial metabolites on cardiovascular risk
Marcin Ufnal
Medical University of Warsaw, Poland

Using germfree animal models to prove the role of the gut microbiota in liver diseases
Philippe Gerard
Inra, France

Link between microbiota & visceral pain: role of bioactive lipids
Cenac Nicolas
Inserm, France

Individual Differences in the Microbiome and Metabolome During Circadian Misalignment and Sleep Restriction: Associations with the Ability to Maintain Wakefulness
Kenneth P. Wright
University of Colorado Boulder, USA

www.microbiota-site.com
Dear Colleagues,

On behalf of the International Society of Microbiota, we are pleased to inform you that the 6th World Congress on Targeting Microbiota will be organized at Porto, Portugal, on October 28-30, 2018.

During both days, many oral and poster communications will be presented and will cover many hot topics:

- Microbiota 2018: Recent Advances & Perspectives
- Challenges of microbiota sequencing and analyzing: How to manage the Big Data of sequencing?
- Challenges of microbiota-host cross-talk understanding and intestinal microbiome signaling to extraintestinal organs
- Microbiota & medicine of tomorrow: Development of effective therapeutic strategies to manipulate the gut microbiota

During Targeting Microbiota 2018, we will try to answer many questions, among them:

- Can we modulate the quality and diversity of human microbiota?
- How to induce durable beneficial changes in gut microbiota?
- Where is the red line of the gut microbiota manipulation?
- What are the strategic mediators of gut microbiota?
- How to understand better the role of bacterial metabolites?
- What is the perfect microbiota “signature” and how to use it as a biomarker to “predict” and/or treat many diseases?
- What is the influence of gut microbiota on the development and progression of chronic diseases?

I do believe that this would be the best future strategy for the 6th World Congress of Targeting Microbiota in 2018: a strong communication between basic, pre-clinical scientists and clinicians.

Microbiota & Medicine of Tomorrow: The Revolution

The scientific committee of ISM and in particular Prof. Marvin Edeas (Institut Cochin, Université Paris Descartes, France), founder of the International Society of Microbiota (ISM) wish to highlight: "...there is a deep transformation in our current medicine where big data and Artificial Intelligence will play a strategic role in the medicine of tomorrow. How all big data generated by microbiota sequencing can be used? Can we talk about Artificial Intelligence and microbiota medicine? We wish to open the door for this kind of discussion..."

So, I hope to meet you at the next meeting in order to capture moments of relationship and scientific inspirations by the many and best scientists we have in the world studying the various aspects of the microbiota.

We very much look forward to seeing you in Berlin for this exciting event

Prof. Peter C. Konturek - President of ISM
Teaching Hospital of the University of Jena, Germany
President of the International Society of Microbiota
International Society of Microbiota

6th World Congress on  
Targeting Microbiota  
October 28-30, 2018 - Hotel Crowne Plaza, Porto, Portugal

Scientific Agenda

Chairpersons:  
Peter Konturek, Marvin Edeas, Knut Rudi, Markus Egert, Ernst Holler, Jan Mazela, Julien Diana, Paul Forsyth, Carole Nicco  
Roberto Pacifici, Nicolas Cenac, Maria Vehreschild, Fadi Abdulqader, Yasubumi Sakakibara

Day 1 – Sunday, October 28

17h00 – 18h00  Registration – Badges & Material Providing

Day 2 – Monday, October 29

7h45  Welcoming & registration of attendees

8h50  Introduction note by the President of ISM Targeting Microbiota 2018, Prof. Peter Konturek

Session 1: Microbiota 2018: Recent Advances & Challenges

Chairs: Marvin Edeas, Maria Vehreschild

9h00  Honor the lodgers? – Interaction between the built environment microbiome and the human microbiome (Skin & Gut)  
Markus Egert, Furtwangen University, Germany

9h25  Impact of antibiotics and microbiota: recent scientific advances and perspectives  
Maria Vehreschild, University Hospital Frankfurt, Germany

9h50  Recent advances on gut microbiota and food intolerances  
Yurdagül Zopf, University of Erlangen-Nuremberg, Germany

10h15  Exploring the role of gut dysbiosis in neuroinflammation and hypertension  
David Durgan, Baylor College of Medicine, USA

10h40  Coffee Break, Network, Exhibition & Poster Session

Chair: Julien Diana, Nicolas Cenac

11h20  Link between microbiota & visceral pain: role of bioactive lipids  
Nicolas Cenac, Inserm, CHU Purpan, France

11h45  Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain  
Francesca Guida, Università degli Studi della Campania “Luigi Vanvitelli”, Italy

11h55  Role of microbes in stem cells transplantation related complication  
Ernst Holler, University Hospital Regensburg, Germany

12h20  Enteric microbiome markers as early predictors of clinical outcome in allogeneic hematopoietic stem cell transplant  
Nicasio Mancini, University Vita-Salute San Raffaele, Italy

12h30  Metagenomic studies on gut microbial diversity in healthy controls and patients with Entamoeba histolytica infections from New Delhi  
Lakshmi Rani Iyer, Jawaharlal Nehru University, New Delhi, India

12h40  Lunch Break, Network, Exhibition & Poster Session
Session 2: Strategies to manipulate microbiota & medicine of tomorrow

Chairs: Markus Egert, Peter Konturek

14h00  Fecal Microbiota Transplant 2018: What’s next?  
Peter Konturek, Teaching Hospital of the University of Jena, Germany

14h25  Phage Therapy strategy to modulate the child stunting microbiota  
Mohammadali Khan Mirzaei, McGill University, Canada

14h50  Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison  
Candice Quin, University of British Columbia, Canada

15h00  Fermented milk by Lactobacillus Delbrueckii CIDCA 133 is able to ameliorate the chemotherapy-induced intestinal mucositis in Balb/c mice  
Mariana Martins Drumond, Universidade Federal de Minas Gerais, Brazil

15h10  Microbiota “friendly” lipid nanoparticles to counteract the gastric infection burden  
Catarina Leal Seabra, University of Porto, Portugal

15h20  Curative properties of three probiotics strains in a mice model of cow-milk allergy: impact on T-helper responses  
Nathalie Esber, University of Paris Descartes, France

15h30  A new freeze-dried formulation to conserve stools over 12 months for fecal transplantation  
Julie Reygner, Université Paris Descartes - Faculté de Pharmacie, France

15h40  Anaerobic cultivated human intestinal microbiota – ACHIM a way to restore intestinal microbiota functions in IBS patients  
Elizabeth Norin, Karolinska Institutet, Sweden

15h50  IL-33 induced by dysbiosis in vaginal microbiota contributes to impaired antiviral immunity against herpes simples virus infection to vaginal mucosa  
Heung Kyu Lee, Korea Advanced Institute of Science and Technology, Korea

16h00  Bacterial quorum sensing molecules manipulate host satiety pathway  
Paola Brun, University of Padova, Italy

16h10  Coffee Break, Network, Exhibition & Poster Session

Session 3: Microbiota sequencing, big data interpretation, and artificial intelligence: myth or reality?

Chair: Yasubumi Sakakibara

16h50  Microbiota sequencing, big data interpretation, and artificial intelligence: myth or reality?  
The aim of this discussion is to connect all the key actors involved in microbiota assessment and analysis: mathematician, computer scientists, bioinformatician, clinician, academics and industrials in order to initiate the discussion about sequencing, big data generating and how to integrate artificial intelligence into microbiota analysis interpretation.

Introduction – Metagenome analysis and bioinformatics method for metagenome assembly: recent advances and perspectives  
Yasubumi Sakakibara, Keio University, Japan

Development of meta-transcriptome analysis method and its application to meta-transcriptome map of common marmoset  
Mika Uehara, Keio University, Japan

17h15  A preliminary study on bioinformatics probiotic database for microbiota  
Melike Yilmaz, Izmir Institute of Technology, Turkey

17h25  Electron-microscopic analysis of skin bacterial microbiota in patients with atopic dermatitis and in healthy human hosts  
Oksaba V. Rybalchenko, St Petersburg State University, Russian Federation

17h35  Improving the accuracy and reproducibility of microbiome measurements across labs  
Thomas Kuri, Zymo Research GmbH, Freiburg, Germany
Day 3 – Tuesday, October 30

8h25 Opening of the second day

Session 4: Strategic role of metabolites and mediators on the microbiota-host cross-talk

Chair: Knut Rudi

8h30 Microbiota and mitochondria inter-talk in hemodialysis patients: a pilot study
Marvin Edeas, Université Paris Descartes, Institut Cochin, France

8h55 Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes
Julien Diana, Institut National de la Santé et de la Recherche Médicale (INSERM), France

9h20 MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response
Antonio Riva, Institute of Hepatology London, Foundation for Liver Research, United Kingdom

9h45 The effect of gut bacterial metabolites on cardiovascular risk
Marcin Ufnal, Medical University of Warsaw, Poland

10h10 The triple interaction diet-microbiome-epigenome: a novel approach to type 1 diabetes
Annalisa Terranegra, Sidra Medicine, Qatar

10h20 Examining the relationship between maternal body size, gestational glucose tolerance, mode of delivery and ethnicity on human milk microbiota at 3 months post-partum
Lauren Lemay-Nedjelski, University of Toronto, Canada

10h30 Coffee Break, Network, Exhibition & Poster Session

Chair: Ernst Holler

11h15 Targeted gut microbiota and short chain fatty acid profile among term and preterm infants
Jan Mazela, Poznan University of Medical Sciences, Poland

11h40 Psycho neuro immunology and gut microbes
Paul Forsythe, McMaster University, Canada

12h05 Using germfree animal models to prove the role of the gut microbiota in liver diseases
Philippe Gérard, INRA, France

12h30 Gut microbiota from infant with cow’s milk allergy leads to atopic orientation in a murine model of CMA
Aurélie Mauras, Université Paris Descartes, France

12h40 Lunch Break, Network, Exhibition & Poster Session
13h45 Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases

Maria Cecilia Giron, University of Padova, Italy

14h10 Individual differences in the microbiome and metabolome during circadian misalignment and sleep restriction: associations with the ability to maintain wakefulness

Kenneth Wright, University of Colorado Boulder, USA

14h35 Sepsis and microbiota: Obstacles, recent advances and strategies

Natalia Beloborodova, Negovsky Research Institute of General Reanimatology, Russia

15h00 Prevalence of akkermansia muciniphila, bacteroides vulgatus and methanobrevibacter smithii in the gut microbiota from relapsing-remitting multiple sclerosis patients

Gislane Lelis Vilela de Oliveira, Barretos School of Health Sciences Dr. Paulo Prata, Brazil

15h25 Current and new approaches for measuring gut-blood barrier permeability

Kinga Jaworska, Medical University of Warsaw, Poland

15h35 Coffee Break, Network, Exhibition & Poster Session

Chairs: Fadi Abdulqader, Paul Forsyth

16h05 Interventional strategies binding the human blood microbiota with the states of health, latent and active tuberculosis

Stefan Panaiotov, National Center of Infectious and Parasitic Diseases, Bulgaria

16h15 Delayed liver regeneration in germ-free mice is normalized following colonization with conventional mouse microbiota

Antony M. Wheatley, National University of Ireland, Ireland

16h25 Influence of nutrition and physical activity on bacterial composition in obese patients

Dejan Reljic, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

16h35 Gut dysbiosis and altered barrier function precedes the appearance of metabolic syndrome in a rat model of maternal food-restriction

Paula Martínez-Oca, University Complutense of Madrid, Spain

16h45 Bile acids, MAIT cell activity and inflammatory parameters and the link to weight in 15 years old children

Gunda Herbert, Helmholtz Center for Environmental Research Leipzig, Germany

16h55 Akkermansia Muciniphila ameliorates inflammatory bowel disease via improvement of gut tight junction and epithelial cell ER stress

Qiaozhu Su, Queen’s University Belfast, United Kingdom

17h05 Is skeletal muscle remodeling associated with gut microbiota signature?

Maxence Jollet, University Montpellier, INRA, France

17h15 Evaluation of the effect of the oral consumption of capsules containing Lactobacillus Paracasei LPC-S01 on the vaginal microbiota of healthy adult women: A randomized, placebo-controlled, double-blind, crossover pilot trial

Valentina Taverniti, Università degli Studi di Milano, Italy

17h25 Intestinal Microbiota as a risk for antimicrobial resistance spread – health and ecological threat

Helena Neto Ferreira, University of Porto, Portugal

17h35 General discussion & Concluding remarks

Among of questions which will be discussed:
- Microbiota 2018: Marketing, Claims & Regulations - Bridging the gap between Marketing Strategy and Science
- Microbiota & Medicine of tomorrow: Can we speculate?

Targeting Microbiota 2018 Awards

17h55 End of Targeting Microbiota 2018